Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/18/2017 04/19/2017 04/20/2017 04/21/2017 04/24/2017 Date
125.9(c) 124.54(c) 123.11(c) 123.01(c) 123.91(c) Last
2 593 568 1 937 177 2 035 165 1 818 883 1 146 299 Volume
-0.13% -1.08% -1.15% -0.08% +0.73% Change
More quotes
Financials ($)
Sales 2017 1 497 M
EBIT 2017 47,7 M
Net income 2017 -36,6 M
Finance 2017 183 M
Yield 2017 -
Sales 2018 1 611 M
EBIT 2018 189 M
Net income 2018 154 M
Finance 2018 258 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 187,92
EV / Sales2017 16,7x
EV / Sales2018 15,5x
Capitalization 25 166 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology.Its product, Jakafi, a JAK1 and JAK2 inhibitor, is... 
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
04/21 NASDAQ 100 MOVERS : Mat, incy
04/20 INCYTE : Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured ..
04/20 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporat..
04/19 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corpo..
04/18 INCYTE : to Report First Quarter Financial Results
04/18 INCYTE : FDA stuns Lilly and Incyte with CRL for much-anticipated RA drug barici..
04/18 Lilly and Incyte`s Loss Is AbbVie and Regeneron`s Gain
04/17 INCYTE CORPORATION : (INCY) Slides on FDA Nod
04/17 INCYTE CORP : Other Events (form 8-K)
04/15 ELI LILLY AND : Incyte Say FDA Issues CRL For Baricitinib
More news
Sector news : Biotechnology & Medical Research - NEC
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
03/31 ACTELION : J&J declares Actelion tender offer a success, sees closing in second ..
03/31DJJOHNSON & JOHNSON : Says Tender Offer to Buy Actelion Successful
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/22? TOP DROPS IN NASDAQ SHORTS: $CMCSA $MYL $AAPL $ATVI $INCY $CSX $Z $STLD $SP..
8
04/21Incyte's Immuno-Oncology And Targeted Therapy Clinical Portfolio To Be Featur.. 
04/21$GILD (+0.4% pre) Gilead Can Lever Up to 4x EBITDA for M&A, BofA/ML Says;..
3
04/21Incyte Co. $INCY PT Set at $167.00 by Credit Suisse Group AG  
04/21$MRUS: Merus announces that data from a Phase 1/2 study of MCLA-128 for the t.. 
More tweets
Qtime:54
News from SeekingAlpha
04/20 Corporate Turnarounds Take Time - Cramer's Mad Money (4/19/17)
04/19 NEWLINK GENETICS : Initiating Coverage With Buy Rating And First Price Target = ..
04/18 INCYTE : Buy On The Drop?
04/18 Olumiant Setback Opens The Door To Rivals
04/18 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Wfc, merc, virt, glo, dkl
Advertisement
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 148 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION22.68%25 166
QUINTILES IMS HOLDINGS..8.15%19 405
LONZA GROUP AG8.28%11 101
CELLTRION, INC.--.--%9 762
SEATTLE GENETICS, INC.23.82%9 319
ALKERMES PLC1.78%8 661
More Results